New deployment option enhances accessibility of virtual stain technology.

  • Pictor Labs showcases virtual stains at USCAP 2026.
  • On-prem deployment option improves accessibility for laboratories.
  • Advancements in pathology diagnostics highlighted.

Pictor Labs has announced the introduction of an on-premises deployment option for its virtual stains technology. This development was unveiled during the annual USCAP 2026 event, emphasizing the company's commitment to enhancing the capabilities of pathology labs. The virtual stains solution is designed to optimize the workflow of pathologists by providing advanced diagnostic tools directly on-site.

By implementing this on-prem deployment, Pictor Labs aims to increase accessibility to its virtual stains technology, allowing laboratories to benefit from these innovative solutions without requiring extensive cloud infrastructure. The introduction of this format is expected to facilitate a seamless integration into existing lab systems, ensuring pathologists can leverage digital advancements efficiently.

This new feature is set to provide a more streamlined approach to pathology diagnostics, reflecting the growing trend towards digital technologies in the field. The on-prem deployment of virtual stains aligns with Pictor Labs' goal of advancing lab innovations that support accurate and timely diagnostics in healthcare.

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

BD Helps Scientists Advance Immunology and Cancer Research with AI-Powered Insights and Automation

Innovative automation enhances cancer research and immunological studies. AI-powered tools improve research…

Pharmacelera Raises $6M to Expand in US and Enhance Drug Discovery Platform

Funding will support growth and technological advancements in drug discovery. Pharmacelera has…

NUNM Receives $1.5 Million Gift to Support Campus Expansion and Future Integrative Medicine Center

Major donation aims to enhance educational opportunities at NUNM. NUNM receives a…

WuXi Biologics and Vertex Enter Research Agreement for T-Cell Engager

Collaboration focuses on advancing T-cell engager therapies for cancer treatment WuXi Biologics…